Notice of Intent to Sole Source.doc
DOC document 120 KB Posted
- Attached to
- Nexcelom Celigo S Cytometer- Control Module-upgrade and Software installation Federal contract opportunity
- Solicitation number
- RFQ-FDA-2021-1242671
About this file
This notice of intent to sole source announces the Food and Drug Administration's requirement to procure a Nexcelom Celigo S Cytometer control module upgrade and software installation on a sole source basis from Nexcelom Bioscience LLC. The procurement will be a fixed price purchase order awarded within fifteen days unless another party can demonstrate the ability to meet the requirement, which includes providing BRAND NAME OR EQUIVALENT parts and accessories compatible with FDA's existing Nexcelom Celigo S cell cytometer. The software installation performed by a Celigo certified engineer requires integrating a new Dell Precision Tower 7820 XL Computer pre-loaded with the current Celigo proprietary software onto the existing cytometer. Responses were due by June 10, 2021 and should be emailed to the point of contact listed.
View the file
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Notice of Intent to Sole Source
Subject: Fixed Price (FFP) Purchase Order Type for the procurement of a Nexcelom Celigo S Cytometer- Control Module-upgrade and Software installation as a Sole Source acquisition to Nexcelom Bioscience LLC, under Request for Quote RFQ-FDA-2021-1242671.
Notice of Intent to Sole Source to: Nexcelom Bioscience LLC.
Pursuant to the authority of 41 USC 3304(a)(1), as implemented by Federal Acquisition Regulation (FAR) Subpart 6.302-1, (there is only one responsible source and no other supplies or services will satisfy agency requirements). The Food and Drug Administration (FDA) intends to award a Sole Source Fixed Price (FFP) Purchase Order Type to Nexcelom Bioscience LLC., located at:
Nexcelom Bioscience LLC.
360 Merrimack Street, Suite 200
Lawrence, Massachusetts 01843, USA
Phone: (978) 327-5340
Fax: (978) 327-5341 sales@nexcelom.com, info@nexcelom.com.
FDA requires BRAND NAME OR EQUIVALENT parts and accessories compatible with the existing Nexcelom Celigo S cell cytometer instrument for the control module replacement and software installation performed by a Celigo certified engineer/technician.
The Celigo S source code control module replacement and software upgrade requires a Dell Precision Tower 7820 XL Computer with operating system Windows 10 IoT Enterprise LTSC, as well as the current release of Celigo software for Windows 10.
The software installation requires integration of the new Celigo Windows 10 Computer with the Celigo cytometer instrument. The new computer shall be pre-loaded with currently released Celigo proprietary image acquisition and analysis software, including Microsoft SQL Server 2019 database managed data.
Integration also includes transfer of the firewire video camera card and the license dongle (for software version 4.0 or newer) from the original Source Code computer (running Celigo software v3.0 or newer) to the new Dell Source code computer. FDA requires parts and accessories compatible with the existing Nexcelom Celigo S cell cytometer instrument for the control module replacement and software installation performed by a Celigo certified engineer/technician.
The associated NAICS Code is: 334516-Analytical Laboratory Instrument Manufacturing.
This notice is not a request for competitive proposals. However, any party that believes it is capable of meeting this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement. Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.
It is anticipated that an award will be issued to Nexcelom Bioscience LLC., within approximately fifteen (15) days after the date of this notice unless the Government determines that any other organization has the capacity to meet this requirement.
Response Date: 12:00 p.m. EST 06/10/2021. Please email responses to Emmanuel Mbah at Emmanuel.mbah@fda.hhs.gov
File details come from the government source that posted it. Updated .